Search Results - "Nguyen, Huy Tram N"

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited by Nguyen, Huy Tram N, Grogan, Patrick, Robins, H Ian

“…Another comparison for gross total resection and MGMT methylation reported survival of around 24 months in patients with MGMT methylated tumours and 18 months…”
Get full text

Epidural Fibrin Sealant Injection for the Management of Cerebrospinal Fluid Leak Following Dural Puncture in Children by Armstrong, Stephanie A, Nguyen, Huy Tram N, Rebsamen, Susan L, Iskandar, Bermans, Stadler, 3rd, James A

“…Cerebrospinal fluid (CSF) leak, intracranial hypotension, and postdural puncture headaches are common following dural punctures. Management usually consists of…”
Get full text

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment by Kong, Xiao-Tang, Nguyen, Nhung T., Choi, Yoon J., Zhang, Guicheng, Nguyen, HuyTram N., Filka, Emese, Green, Stacey, Yong, William H., Liau, Linda M., Green, Richard M., Kaprealian, Tania, Pope, Whitney B., Nghiemphu, P. Leia, Cloughesy, Timothy, Lassman, Andrew, Lai, Albert

“…To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by…”
Get full text

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide by Rapkins, Robert W, Wang, Fan, Nguyen, HuyTram N, Cloughesy, Timothy F, Lai, Albert, Ha, Wendy, Nowak, Anna K, Hitchins, Megan P, McDonald, Kerrie L

“…Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT…”
Get full text

Bevacizumab (Bev) to reduce the negative impact of glioblastoma (GBM) tumor size on survival from first recurrence by Nguyen, Huy Tram N., Liu, Liang Yen, Nguyen, Nhung T, Lenchner, Daniel, Dovek, Laura, Harris, Robert J., Ellingson, Benjamin M., Ozer, Byram H, Ravelo, Arliene, Sommer, Nicolas, Sim, Myung Shin, Elashoff, Robert M., Green, Richard M., Nghiemphu, Phioanh Leia, Cloughesy, Timothy Francis, Lai, Albert

“…Abstract only 2052 Background: Bev was FDA approved for recurrent GBM in 2009. However, the survival benefit from Bev in GBM remains to be demonstrated…”
Get full text

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide by Robins, H Ian, Nguyen, HuyTram N, Field, Aaron, Howard, Steven, Salamat, Shahriar, Deming, Dustin A

“…Tumor Treating Field (TTFields) therapy has demonstrated efficacy in a Phase 3 study of newly diagnosed glioblastoma (GB) following radiation (RT) and…”
Get full text

Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity by Nguyen, HuyTram N, Vo, Kevin B H, Howard, Steven, Salamat, M Shahriar, Rowely, Howard, Robins, H Ian

“…Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of…”
Get full text

Epidural Fibrin Sealant Injection for the Management of Cerebrospinal Fluid Leak Following Dural Puncture in Children by Armstrong, Stephanie A, Nguyen, Huy Tram N, Rebsamen, Susan L, Iskandar, Bermans, Stadler, James A

Get full text